Skip to content

Comparison Between Primary and Secondary Implant Stability of Hybrid Versus Resorbable Blast Media (RBM) Surfaces Using Resonance Frequency Analysis

Comparison Between Primary and Secondary Implant Stability of Hybrid Versus Resorbable Blast Media (RBM) Surfaces Using Resonance Frequency Analysis

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06620315
Acronym
IMPLANTSTABIL
Enrollment
60
Registered
2024-10-01
Start date
2023-01-01
Completion date
2024-03-01
Last updated
2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IMPANT STABILITY, Implant Complication

Brief summary

• To compare primary stability (during initial loading of implant) and secondary stability (after 12 weeks of implant loading) which are denoted as ISQ value of Hybrid (DIO UFII) versus Resorbable blast media (RBM) (Osstem TSII) implant surfaces.

Detailed description

An approval from the hospital ethical committee will be obtained for this study. As a protocol all patients presenting to Institute of Dentistry, CMH Lahore Medical College will be examined in general OPD and those patients who fulfill the inclusion and exclusion criteria will be referred to Prosthodontics department. After history, complete oral examination and informed consent. Patients will be divided into two groups by lottery method; In Group 1 Hybrid (sand blasted acid etched implants) will be place. In Group 2 Resorbable Blast Media (RBM) implant surfaces will be placed. On the basis of randomized study the patients will be selected for the study to measure implant primary stability with a resonance frequency analyzer at the time of initial loading of implant, starting with an assessment immediately following implant placement with insertion torque of 30 Ncm and then secondary stability at 12 weeks post operatively by using Ostell Mentor. This instrument on each implant by inserting a standardized abutment (Smartpeg) of fixed length into each implant. The transducer probe (Osstell mentor probe) will be held so that the probe tip was aimed at the small magnet on top of the Smartpeg at a distance of 2-3 mm in both the buccal and lingual directions, and the mean of these measurements will then be calculated. The probe will be held still during the pulsing time until the instrument beeped and the displayed the ISQ value. ISQ1 will be evaluated immediately during initial implant loading which will be primary stability and ISQ2 will be evaluated after 12 weeks of implant placement when implant is properly osseointegrated, which will be secondary stability of an implant. The implant fixtures will be DIO UF II for the Hybrid implants and the Osstem TSII plus system for the RBM implants. Data would be stratified for age, gender and implant site to address the effect modifiers.

Interventions

COMBINATION_PRODUCTRBM

Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability

COMBINATION_PRODUCTsand blasted implant

sand blasted implant

Sponsors

Shaheed Zulfiqar Ali Bhutto Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* o Age between 20 to 50 years. * Both male and female patients will be selected. * Patients suitable for implant restorations on CBCT will be diagnosed by; 1. Bone height (minimum of 12mm) 2. Bone width (minimum of 5mm) 3. Proximity with vital structures (nerves, blood vessels)

Exclusion criteria

* o Patients with diabetes, Parkinson's disease, myasthenia gravis and bulbar palsy * Diseases with either a strong connection to emotional stress or impairing mental health like depression, anxiety, sleeping disorder on history examination. * Patients with poor oral hygiene. * Patients with parafunctional habits of severe clenching habit, bruxism. * Heavy smokers * Patients who had undergone radiotherapy or chemotherapy. * Patients with osteoarthritis, osteoporosis. * Patients taking bisphosphonates

Design outcomes

Primary

MeasureTime frameDescription
Primary Stabilityup to 3 monthsabsence of clinically detectable implant mobility

Secondary

MeasureTime frameDescription
Secondary Stability3 monthsabsence of clinically detectable implant mobility

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026